康希諾：mRNA 新冠疫苗已進入臨牀Ⅱ期試驗階段

智通財經
2022.09.05 23:23
康希諾近期接受投資者調研時稱，公司的 mRNA 新冠疫苗已進入臨牀Ⅱ期試驗階段，預計今年年底前能夠完成大部分的現場工作並收集到初步數據。我們更多的是想通過新冠疫苗這個產品驗證我們的 mRNA 平台技術，走通後加速推進其他候選產品的開發，比如帶狀皰疹、流感等。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.